StonvexLoading…
StonvexCore line items from RCAT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $15.47M | $40.73M | $14.49M | $1.13M |
Operating Income | $-27.30M | $-66.60M | $-42.66M | $-25.12M |
Net Income | $-26.55M | $-72.08M | $-52.42M | $-13.28M |
EPS (Diluted) | $-0.22 | $-0.73 | $-0.57 | $-0.41 |
Total Assets | $281.88M | $273.68M | $286.02M | $121.37M |
Total Liabilities | $43.15M | $27.84M | $32.75M | $25.80M |
Cash & Equivalents | $131.92M | $167.87M | $206.43M | $65.93M |
Free Cash Flow OCF − CapEx | $-38.73M | $-95.78M | $-53.91M | $-29.38M |
Shares Outstanding | 121.84M | 120.07M | 118.16M | 98.51M |